Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0002871 (
anemia
)
52,094
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The
ser
ine
inc
orporator (SERINC) proteins are multipass transmembrane proteins that affect sphingolipid and phosphatidylserine synthesis. Human SERINC5 and
SERINC3
were recently shown to possess antiretroviral activity for a number of retroviruses, including human immunodeficiency virus (HIV), murine leukemia virus (MLV), and equine infectious
anemia
virus (EIAV). In the case of MLV, the glycosylated Gag (glyco-Gag) protein was shown to counteract SERINC5-mediated restriction in
in vitro
experiments and the viral envelope was found to determine virion sensitivity or resistance to SERINC5. However, nothing is known about the
in vivo
function of SERINC5. Antiretroviral function of a host factor
in vitro
is not always associated with antiretroviral function
in vivo
Using SERINC5
-/-
mice that we had generated, we showed that mouse SERINC5 (mSERINC5) restriction of MLV infection
in vivo
is influenced not only by glyco-Gag but also by the retroviral envelope. Finally, we also examined the
in vivo
function of the other SERINC gene with known antiretroviral functions,
SERINC3
. By using
SERINC3
-/-
mice, we found that the murine homologue, mSERINC3, had no antiretroviral role either
in vivo
or
in vitro
To our knowledge, this report provides the first data showing that SERINC5 restricts retrovirus infection
in vivo
and that restriction of retrovirus infectivity
in vivo
is dependent on the presence of both glyco-Gag and the viral envelope.
IMPORTANCE
This study examined for the first time the
in vivo
function of the
ser
ine
inc
orporator (SERINC) proteins during retrovirus infection.
SERINC3
and SERINC5 (
SERINC3
/5) restrict a number of retroviruses, including human immunodeficiency virus 1 (HIV-1) and murine leukemia virus (MLV), by blocking their entry into cells. Nevertheless, HIV-1 and MLV encode factors, Nef and glycosylated Gag, respectively, that counteract
SERINC3
/5
in vitro
We recently developed
SERINC3
and SERINC5 knockout mice to examine the
in vivo
function of these genes. We found that SERINC5 restriction is dependent on the absence of glycosylated Gag and the expression of a specific viral envelope glycoprotein. On the other hand,
SERINC3
had no antiviral function. Our findings have implications for the development of therapeutics that target SERINC5 during retrovirus infection.
...
PMID:SERINC5 Potently Restricts Retrovirus Infection
In Vivo
. 3266 69